probiotics+b ratiopharm (paziņots) kapsula
sigmar italia s.p.a. - kapsula
travoprost teva pharma 40 mikrogrami/ml acu pilieni, šķīdums
teva pharma b.v., netherlands - travoprosts - acu pilieni, šķīdums - 40 mikrogrami/ml
fulvestrant stada 250 mg šķīdums injekcijām pilnšļircē
stada arzneimittel ag, germany - fulvestrants - Šķīdums injekcijām pilnšļircē - 250 mg/5 ml
nintedanib teva 100 mg mīkstās kapsulas
teva gmbh, germany - nintedanibs - kapsula, mīkstā - 100 mg
nintedanib teva 150 mg mīkstās kapsulas
teva gmbh, germany - nintedanibs - kapsula, mīkstā - 150 mg
paliperidone teva 75 mg ilgstošās darbības suspensija injekcijām
teva gmbh, germany - paliperidons - ilgstošās darbības suspensija injekcijām - 75 mg
paliperidone teva 100 mg ilgstošās darbības suspensija injekcijām
teva gmbh, germany - paliperidons - ilgstošās darbības suspensija injekcijām - 100 mg
paliperidone teva 150 mg ilgstošās darbības suspensija injekcijām
teva gmbh, germany - paliperidons - ilgstošās darbības suspensija injekcijām - 150 mg
dimethyl fumarate teva
teva gmbh - dimethyl fumarate - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmoloģiskie līdzekļi - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).